G Kees Hovingh

List of Publications by Year in Descending Order

144 papers	17,575 citations	53 h-index	132 g-index
156 ext. papers	21,829 ext. citations	9.5 avg, IF	6.06 L-index

#	Paper	IF	Citations
144	Worldwide experience of homozygous familial hypercholesterolaemia: retrospective cohort study.. *Lancet, The*, **2022**,	40	4
143	Genetically Predicted Neutrophil-to-Lymphocyte Ratio and Coronary Artery Disease: Evidence From Mendelian Randomization.. *Circulation Genomic and Precision Medicine*, **2022**, CIRCGEN121003553	5.2	0
142	Letter by Tromp et al Regarding Article, "Large-Scale Screening for Monogenic and Clinically Defined Familial Hypercholesterolemia in Iceland".. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2022**, 42, e44-e45	9.4	
141	Interleukin 6 in diabetes, chronic kidney disease and cardiovascular disease: mechanisms and therapeutic perspectives.. *Expert Review of Clinical Immunology*, **2022**,	5.1	2
140	LDL-C calculated by Friedewald, Martin-Hopkins, or NIH Equation 2 versus beta-quantification: pooled alirocumab trials. *Journal of Lipid Research*, **2021**, 100148	6.3	1
139	Next-generation sequencing to confirm clinical familial hypercholesterolemia. *European Journal of Preventive Cardiology*, **2021**, 28, 875-883	3.9	7
138	Intronic variant screening with targeted next-generation sequencing reveals first pseudoexon in LDLR in familial hypercholesterolemia. *Atherosclerosis*, **2021**, 321, 14-20	3.1	4
137	ANGPTL3 Inhibition With Evinacumab Results in Faster Clearance of IDL and LDL apoB in Patients With Homozygous Familial Hypercholesterolemia-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 1753-1759	9.4	18
136	Marked plaque regression in homozygous familial hypercholesterolemia. *Atherosclerosis*, **2021**, 327, 13-17	3.1	9
135	Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2021**, 41, 934-943	9.4	3
134	High density lipoproteins mediate in vivo protection against staphylococcal phenol-soluble modulins. *Scientific Reports*, **2021**, 11, 15357	4.9	0
133	The iterative lipid impact on inflammation in atherosclerosis. *Current Opinion in Lipidology*, **2021**, 32, 286-292	4.4	4
132	Regional Variations in Alirocumab Dosing Patterns in Patients with Heterozygous Familial Hypercholesterolemia During an Open-Label Extension Study. *Cardiovascular Drugs and Therapy*, **2020**, 34, 515-523	3.9	2
131	The identification and function of a Netrin-1 mutation in a pedigree with premature atherosclerosis. *Atherosclerosis*, **2020**, 301, 84-92	3.1	6
130	ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2020**, 14, 207-217.e7	4.9	16
129	Netrin-1 and the Grade of Atherosclerosis Are Inversely Correlated in Humans. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2020**, 40, 462-472	9.4	9
128	Association of Factor V Leiden With Subsequent Atherothrombotic Events: A GENIUS-CHD Study of Individual Participant Data. *Circulation*, **2020**, 142, 546-555	16.7	5

127	Common gene variants in ASGR1 gene locus associate with reduced cardiovascular risk in absence of pleiotropic effects. *Atherosclerosis*, **2020**, 306, 15-21	3.1	3
126	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. *American Heart Journal*, **2020**, 229, 61-69	4.9	53
125	Statin therapy reduces plasma angiopoietin-like 3 (ANGPTL3) concentrations in hypercholesterolemic patients via reduced liver X receptor (LXR) activation. *Atherosclerosis*, **2020**, 315, 68-75	3.1	2
124	Next-generation sequencing to confirm clinical familial hypercholesterolemia. *European Journal of Preventive Cardiology*, **2020**, 2047487320942996	3.9	5
123	A neutralizing antibody against DKK1 does not reduce plaque formation in classical murine models of atherosclerosis: Is the therapeutic potential lost in translation?. *Atherosclerosis*, **2020**, 314, 1-9	3.1	1
122	Evinacumab for Homozygous Familial Hypercholesterolemia. *New England Journal of Medicine*, **2020**, 383, 711-720	59.2	166
121	Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement. *Lancet Diabetes and Endocrinology,the*, **2020**, 8, 50-67	18.1	48
120	Association of Genetic Variants Related to Combined Exposure to Lower Low-Density Lipoproteins and Lower Systolic Blood Pressure With Lifetime Risk of Cardiovascular Disease. *JAMA - Journal of the American Medical Association*, **2019**, 322, 1381-1391	27.4	79
119	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002470	5.2	13
118	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. *Circulation Genomic and Precision Medicine*, **2019**, 12, e002471	5.2	14
117	Impact of Age on the Efficacy and Safety of Alirocumab in Patients with Heterozygous Familial Hypercholesterolemia. *Cardiovascular Drugs and Therapy*, **2019**, 33, 69-76	3.9	9
116	Individualized low-density lipoprotein cholesterol reduction with alirocumab titration strategy in heterozygous familial hypercholesterolemia: Results from an open-label extension of the ODYSSEY LONG TERM trial. *Journal of Clinical Lipidology*, **2019**, 13, 138-147	4.9	10
115	The clinical and molecular diversity of homozygous familial hypercholesterolemia in children: Results from the GeneTics of clinical homozygous hypercholesterolemia (GoTCHA) study. *Journal of Clinical Lipidology*, **2019**, 13, 272-278	4.9	3
114	Triglyceride-Rich Lipoprotein Cholesterol and Risk of Cardiovascular Events Among Patients Receiving Statin Therapy in the TNT Trial. *Circulation*, **2018**, 138, 770-781	16.7	65
113	Genetics of familial hypercholesterolemia: a tool for development of novel lipid lowering pharmaceuticals?. *Current Opinion in Lipidology*, **2018**, 29, 80-86	4.4	4
112	PCSK9 inhibitors in clinical practice: Delivering on the promise?. *Atherosclerosis*, **2018**, 270, 205-210	3.1	36
111	Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. *European Heart Journal*, **2018**, 39, 2526-2539	9.5	156
110	Efficacy and Safety of Pitavastatin in Children and Adolescents with Familial Hypercholesterolemia in Japan and Europe. *Journal of Atherosclerosis and Thrombosis*, **2018**, 25, 422-429	4	16

109	New prospects for PCSK9 inhibition?. *European Heart Journal*, **2018**, 39, 2600-2601	9.5	9
108	2017 Update of ESC/EAS Task Force on practical clinical guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular disease or in familial hypercholesterolaemia. *European Heart Journal*, **2018**, 39, 1131-1143	9.5	132
107	Effect of atorvastatin, cholesterol ester transfer protein inhibition, and diabetes mellitus on circulating proprotein subtilisin kexin type 9 and lipoprotein(a) levels in patients at high cardiovascular risk. *Journal of Clinical Lipidology*, **2018**, 12, 130-136	4.9	27
106	Homozygous familial hypercholesterolaemia: light at the end of the tunnel. *European Heart Journal*, **2018**, 39, 1169-1171	9.5	3
105	Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. *European Heart Journal*, **2018**, 39, 2589-2596	9.5	56
104	Ethnic differences in plasma lipid levels in a large multiethnic cohort: The HELIUS study. *Journal of Clinical Lipidology*, **2018**, 12, 1217-1224.e1	4.9	9
103	Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. *Journal of the American College of Cardiology*, **2018**, 72, 662-680	15.1	215
102	Complete and Partial Lecithin:Cholesterol Acyltransferase Deficiency Is Differentially Associated With Atherosclerosis. *Circulation*, **2018**, 138, 1000-1007	16.7	35
101	Inhibiting PCSK9 - biology beyond LDL control. *Nature Reviews Endocrinology*, **2018**, 15, 52-62	15.2	49
100	A Deep Intronic Variant in LDLR in Familial Hypercholesterolemia. *Circulation Genomic and Precision Medicine*, **2018**, 11, e002385	5.2	12
99	Alirocumab dosing patterns during 40 months of open-label treatment in patients with heterozygous familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2018**, 12, 1463-1470	4.9	2
98	Familial hypercholesterolemia treatments: Guidelines and new therapies. *Atherosclerosis*, **2018**, 277, 483-492	3.1	72
97	Overview of the current status of familial hypercholesterolaemia care in over 60 countries - The EAS Familial Hypercholesterolaemia Studies Collaboration (FHSC). *Atherosclerosis*, **2018**, 277, 234-255	3.1	93
96	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. *Journal of Clinical Lipidology*, **2018**, 12, 1493-1501.e11	4.9	6
95	Long-term safety and efficacy of alirocumab in patients with heterozygous familial hypercholesterolemia: An open-label extension of the ODYSSEY program. *Atherosclerosis*, **2018**, 278, 307-314	3.1	30
94	Achieved LDL cholesterol levels in patients with heterozygous familial hypercholesterolemia: A model that explores the efficacy of conventional and novel lipid-lowering therapy. *Journal of Clinical Lipidology*, **2018**, 12, 972-980.e1	4.9	11
93	Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 monoclonal antibody alirocumab vs placebo in patients with heterozygous familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2017**, 11, 195-203.e4	4.9	45
92	Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study. *Lancet Diabetes and Endocrinology,the*, **2017**, 5, 280-290	18.1	148

91	Plasma lipoprotein(a) levels in patients with homozygous autosomal dominant hypercholesterolemia. *Journal of Clinical Lipidology*, **2017**, 11, 507-514	4.9	12
90	Systematic Evaluation of Pleiotropy Identifies 6 Further Loci Associated With Coronary Artery Disease. *Journal of the American College of Cardiology*, **2017**, 69, 823-836	15.1	146
89	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 1206-1212	9.4	35
88	GPIHBP1 autoantibodies in a patient with unexplained chylomicronemia. *Journal of Clinical Lipidology*, **2017**, 11, 964-971	4.9	19
87	Identification and Management of Statin-Associated Symptoms in Clinical Practice: Extension of a Clinician Survey to 12 Further Countries. *Cardiovascular Drugs and Therapy*, **2017**, 31, 187-195	3.9	15
86	The effect of statins on cardiovascular outcomes by smoking status: A systematic review and meta-analysis of randomized controlled trials. *Pharmacological Research*, **2017**, 122, 105-117	10.2	16
85	Long-term safety, tolerability, and efficacy of evolocumab in patients with heterozygous familial hypercholesterolemia. *Journal of Clinical Lipidology*, **2017**, 11, 1448-1457	4.9	32
84	Effects of Supra-Physiological Levothyroxine Dosages on Liver Parameters, Lipids and Lipoproteins in Healthy Volunteers: A Randomized Controlled Crossover Study. *Scientific Reports*, **2017**, 7, 14174	4.9	4
83	Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis. *PLoS Medicine*, **2017**, 14, e1002383	11.6	223
82	European Society of Cardiology/European Atherosclerosis Society Task Force consensus statement on proprotein convertase subtilisin/kexin type 9 inhibitors: practical guidance for use in patients at very high cardiovascular risk. *European Heart Journal*, **2017**, 38, 2245-2255	9.5	105
81	ABCA8 Regulates Cholesterol Efflux and High-Density Lipoprotein Cholesterol Levels. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 2147-2155	9.4	34
80	ANGPTL3 Inhibition in Homozygous Familial Hypercholesterolemia. *New England Journal of Medicine*, **2017**, 377, 296-297	59.2	183
79	Association of High-Density Lipoprotein-Cholesterol Versus Apolipoprotein A-I With Risk of Coronary Heart Disease: The European Prospective Investigation Into Cancer-Norfolk Prospective Population Study, the Atherosclerosis Risk in Communities Study, and the Womens Health Study. *Journal of the American Heart Association*, **2017**, 6,	6	9
78	Diabetes: Anti-PCSK9 antibodies - beneficial or inducers of diabetes?. *Nature Reviews Endocrinology*, **2017**, 13, 694-695	15.2	2
77	Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors. *European Journal of Preventive Cardiology*, **2017**, 24, 1383-1401	3.9	32
76	Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study. *Atherosclerosis*, **2017**, 256, 47-52	3.1	38
75	Carriers of the PCSK9 R46L Variant Are Characterized by an Antiatherogenic Lipoprotein Profile Assessed by Nuclear Magnetic Resonance Spectroscopy-Brief Report. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2017**, 37, 43-48	9.4	19
74	New Drugs for Atherosclerosis. *Canadian Journal of Cardiology*, **2017**, 33, 350-357	3.8	15

73	Open-label therapy with alirocumab in patients with heterozygous familial hypercholesterolemia: Results from three years of treatment. *International Journal of Cardiology*, **2017**, 228, 754-760	3.2	15
72	Very low LDL-cholesterol concentrations achieved: which target is next?. *Lancet, The*, **2017**, 390, 1930-1931	47.1	3
71	Selection of individuals for genetic testing for familial hypercholesterolaemia: development and external validation of a prediction model for the presence of a mutation causing familial hypercholesterolaemia. *European Heart Journal*, **2017**, 38, 565-573	9.5	28
70	A rare variant in MCF2L identified using exclusion linkage in a pedigree with premature atherosclerosis. *European Journal of Human Genetics*, **2016**, 24, 86-91	5.3	7
69	Double-heterozygous autosomal dominant hypercholesterolemia: Clinical characterization of an underreported disease. *Journal of Clinical Lipidology*, **2016**, 10, 1462-1469	4.9	20
68	The genetics of blood pressure regulation and its target organs from association studies in 342,415 individuals. *Nature Genetics*, **2016**, 48, 1171-1184	36.3	251
67	Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia. *Atherosclerosis*, **2016**, 251, 263-265	3.1	17
66	Defining severe familial hypercholesterolaemia and the implications for clinical management: a consensus statement from the International Atherosclerosis Society Severe Familial Hypercholesterolemia Panel. *Lancet Diabetes and Endocrinology,the*, **2016**, 4, 850-61	18.1	215
65	Retrospective analysis of cohort database: Phenotypic variability in a large dataset of patients confirmed to have homozygous familial hypercholesterolemia. *Data in Brief*, **2016**, 7, 1458-62	1.2	2
64	Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia. *Atherosclerosis*, **2016**, 246, 1-6	3.1	7
63	Identification and management of patients with statin-associated symptoms in clinical practice: A clinician survey. *Atherosclerosis*, **2016**, 245, 111-7	3.1	43
62	Heterogeneous impact of classic atherosclerotic risk factors on different arterial territories: the EPIC-Norfolk prospective population study. *European Heart Journal*, **2016**, 37, 880-9	9.5	24
61	Statins in Familial Hypercholesterolemia: Consequences for Coronary Artery Disease and All-Cause Mortality. *Journal of the American College of Cardiology*, **2016**, 68, 252-260	15.1	103
60	Meta-analysis of genome-wide association studies of HDL cholesterol response to statins. *Journal of Medical Genetics*, **2016**, 53, 835-845	5.8	28
59	Pooling and expanding registries of familial hypercholesterolaemia to assess gaps in care and improve disease management and outcomes: Rationale and design of the global EAS Familial Hypercholesterolaemia Studies Collaboration. *Atherosclerosis Supplements*, **2016**, 22, 1-32	1.7	60
58	Children with hypercholesterolemia of unknown cause: Value of genetic risk scores. *Journal of Clinical Lipidology*, **2016**, 10, 851-859	4.9	20
57	Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study. *Atherosclerosis*, **2016**, 248, 238-44	3.1	35
56	Targeted exonic sequencing of GWAS loci in the high extremes of the plasma lipids distribution. *Atherosclerosis*, **2016**, 250, 63-8	3.1	9

55	Effects of the cholesteryl ester transfer protein inhibitor, TA-8995, on cholesterol efflux capacity and high-density lipoprotein particle subclasses. *Journal of Clinical Lipidology*, **2016**, 10, 1137-1144.e3	4.9	20
54	High-dose atorvastatin is superior to moderate-dose simvastatin in preventing peripheral arterial disease. *Heart*, **2015**, 101, 356-62	5.1	33
53	The effect of an apolipoprotein A-I-containing high-density lipoprotein-mimetic particle (CER-001) on carotid artery wall thickness in patients with homozygous familial hypercholesterolemia: The Modifying Orphan Disease Evaluation (MODE) study. *American Heart Journal*, **2015**, 169, 736-742.e1	4.9	53
52	The impact of LDLR function on fibroblast growth factor 21 levels. *Atherosclerosis*, **2015**, 241, 322-5	3.1	
51	Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?. *Circulation*, **2015**, 132, 433-40	16.7	21
50	Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet, The*, **2015**, 385, 2153-61	40	78
49	HDL re-examined. *Current Opinion in Lipidology*, **2015**, 26, 127-32	4.4	28
48	Association between familial hypercholesterolemia and prevalence of type 2 diabetes mellitus. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1029-36	27.4	246
47	Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. *European Heart Journal*, **2015**, 36, 2425-37	9.5	430
46	Familial hypercholesterolaemia: A global call to arms. *Atherosclerosis*, **2015**, 243, 257-9	3.1	123
45	New Approaches in Detection and Treatment of Familial Hypercholesterolemia. *Current Cardiology Reports*, **2015**, 17, 109	4.2	20
44	Dyslipidaemia: Lysosomal acid lipase deficiency-a cautious leap forward. *Nature Reviews Endocrinology*, **2015**, 11, 696-7	15.2	3
43	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia. *European Heart Journal*, **2015**, 36, 2996-3003	9.5	311
42	Myocardial infarction in a 36-year-old man with combined ABCA1 and APOA-1 deficiency. *Journal of Clinical Lipidology*, **2015**, 9, 396-9	4.9	4
41	Analysis of vitamin D levels in patients with and without statin-associated myalgia - a systematic review and meta-analysis of 7 studies with 2420 patients. *International Journal of Cardiology*, **2015**, 178, 111-6	3.2	129
40	Annexin A5 haplotypes in familial hypercholesterolemia: lack of association with carotid intima-media thickness and cardiovascular disease risk. *Atherosclerosis*, **2015**, 238, 195-200	3.1	7
39	Exome sequencing identifies rare LDLR and APOA5 alleles conferring risk for myocardial infarction. *Nature*, **2015**, 518, 102-6	50.4	463
38	PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2015**, 385, 331-40	40	493

37	Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial. *Lancet, The*, **2015**, 385, 341-50	40	497
36	Homozygous autosomal dominant hypercholesterolaemia in the Netherlands: prevalence, genotype-phenotype relationship, and clinical outcome. *European Heart Journal*, **2015**, 36, 560-5	9.5	283
35	Impact of statin therapy on coronary plaque composition: a systematic review and meta-analysis of virtual histology intravascular ultrasound studies. *BMC Medicine*, **2015**, 13, 229	11.4	126
34	A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. *Scientific Reports*, **2015**, 5, 9902	4.9	109
33	Statin intolerance - an attempt at a unified definition. Position paper from an International Lipid Expert Panel. *Archives of Medical Science*, **2015**, 11, 1-23	2.9	252
32	Statin-associated muscle symptoms: impact on statin therapy-European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. *European Heart Journal*, **2015**, 36, 1012-22	9.5	770
31	PCSK9 inhibitors: Novel therapeutic agents for the treatment of hypercholesterolemia. *European Journal of Pharmacology*, **2015**, 763, 38-47	5.3	26
30	Cholesterol ester transfer protein inhibition by TA-8995 in patients with mild dyslipidaemia (TULIP): a randomised, double-blind, placebo-controlled phase 2 trial. *Lancet, The*, **2015**, 386, 452-60	40	140
29	Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology. *Atherosclerosis*, **2015**, 241, 169-75	3.1	114
28	Genetic studies of body mass index yield new insights for obesity biology. *Nature*, **2015**, 518, 197-206	50.4	2687
27	Identification of four novel genes contributing to familial elevated plasma HDL cholesterol in humans. *Journal of Lipid Research*, **2014**, 55, 1693-701	6.3	17
26	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. *Journal of the American College of Cardiology*, **2014**, 64, 485-94	15.1	372
25	HDL and cardiovascular disease. *Lancet, The*, **2014**, 384, 618-625	40	389
24	Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia. *Journal of the American College of Cardiology*, **2014**, 64, 1418-26	15.1	74
23	Defining the role of common variation in the genomic and biological architecture of adult human height. *Nature Genetics*, **2014**, 46, 1173-86	36.3	1339
22	Statin and the risk of renal-related serious adverse events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and other placebo-controlled trials. *American Journal of Cardiology*, **2014**, 113, 2018-20	3	32
21	Eprotirome in patients with familial hypercholesterolaemia (the AKKA trial): a randomised, double-blind, placebo-controlled phase 3 study. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 455-63	18.1	68
20	The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management. *Lancet Diabetes and Endocrinology,the*, **2014**, 2, 655-66	18.1	357

19	Adrenal Function in females with low plasma HDL-C due to mutations in ABCA1 and LCAT. *PLoS ONE*, **2014**, 9, e90967	3.7	9
18	Common genetic variants do not associate with CAD in familial hypercholesterolemia. *European Journal of Human Genetics*, **2014**, 22, 809-13	5.3	2
17	Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. *Nature Communications*, **2014**, 5, 5068	17.4	160
16	Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society. *European Heart Journal*, **2014**, 35, 2146-57	9.5	614
15	Mutations in STAP1 are associated with autosomal dominant hypercholesterolemia. *Circulation Research*, **2014**, 115, 552-5	15.7	114
14	HDL does not influence the polarization of human monocytes toward an alternative phenotype. *International Journal of Cardiology*, **2014**, 172, 179-84	3.2	18
13	Gene-centric meta-analysis in 87,736 individuals of European ancestry identifies multiple blood-pressure-related loci. *American Journal of Human Genetics*, **2014**, 94, 349-60	11	131
12	Severe heterozygous familial hypercholesterolemia and risk for cardiovascular disease: a study of a cohort of 14,000 mutation carriers. *Atherosclerosis*, **2014**, 233, 219-23	3.1	135
11	eNOS activation by HDL is impaired in genetic CETP deficiency. *PLoS ONE*, **2014**, 9, e95925	3.7	30
10	Mutation in KERA identified by linkage analysis and targeted resequencing in a pedigree with premature atherosclerosis. *PLoS ONE*, **2014**, 9, e98289	3.7	5
9	Discovery and refinement of loci associated with lipid levels. *Nature Genetics*, **2013**, 45, 1274-1283	36.3	1904
8	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. *Journal of the American College of Cardiology*, **2013**, 62, 1966-1976	15.1	91
7	High density lipoprotein as a source of cholesterol for adrenal steroidogenesis: a study in individuals with low plasma HDL-C. *Journal of Lipid Research*, **2013**, 54, 1698-1704	6.3	37
6	Diagnosis and treatment of familial hypercholesterolaemia. *European Heart Journal*, **2013**, 34, 962-71	9.5	187
5	Advances in genetics show the need for extending screening strategies for autosomal dominant hypercholesterolaemia. *European Heart Journal*, **2012**, 33, 1360-6	9.5	66
4	Compromised LCAT function is associated with increased atherosclerosis. *Circulation*, **2005**, 112, 879-84	16.7	135
3	Inherited disorders of HDL metabolism and atherosclerosis. *Current Opinion in Lipidology*, **2005**, 16, 139-45	4.4	84
2	A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. *Journal of the American College of Cardiology*, **2004**, 44, 1429-35	15.1	103

1	The role of the ABCA1 transporter and cholesterol efflux in familial hypoalphalipoproteinemia. *Journal of Lipid Research*, **2003**, 44, 1251-5	6.3	35